GIMBERT JOAN PONS Form SC 13G/A May 25, 2004

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

\_\_\_\_\_

Under the Securities Exchange Act of 1934

SCHEDULE 13G Amendment No. 1

INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Manhattan Pharmaceuticals, Inc.
----(Name of Issuer)

Common Stock, \$0.001 par value
----(Title of Class of Securities)

563118207 -----(CUSIP Number)

February 26, 2004

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- |\_| Rule 13d-1(b)
- |X| Rule 13d-1(c)
- |\_| Rule 13d-1(d)

Page 1 of 7 Pages

SCHEDULE 13G

CUSIP No. 563118207 Page 2 of 7 Pages

1)	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON					
	Oleoyl-Estrone Developmen	ts SL				
2)	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (a)  _   (b)  _					
3)	SEC USE ONLY					
4)	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Barcelona, Spain					
		5)	SOLE VOTING POWER			
			3,957,037			
	NUMBER	6)	SHARED VOTING POWER	\\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-		
	OF SHARES		0			
	BENEFICIALLY OWNED BY	7)	SOLE DISPOSITIVE PO	 )WER		
	EACH REPORTING		3,957,037			
	PERSON WITH	8)	SHARED DISPOSITIVE	POWER		
			0			
 9)	AGGREGATE AMOUNT BENEFICI	ALLY OW		PERSON		
	3,957,037					
 10)	 CHECK BOX IF THE AGGREGAT	E AMOUN	TIN ROW (9) EXCLUDES	CERTAIN SHARES		
				1_1		
 11)	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
,	16.9%					
 12)						
CO						
		SC	CHEDULE 13G			
CUS	CUSIP No. 563118207 Page 3 of 7 Pages					
1)	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON					
	Joan Pons Gimbert					
 2)	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)  _					

			(b)  _		
3)	SEC USE ONLY				
4)	CITIZENSHIP OR PLACE OF ORGANIZATION				
	Spain				
	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5)	SOLE VOTING POWER		
			3,957,037(1)		
		6)	SHARED VOTING POWER		
			0		
		7)	SOLE DISPOSITIVE POWER		
			3,957,037(1)		
		8)	SHARED DISPOSITIVE POWER		
			0		
9)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	3,957,037(1)				
10)	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
			I_I		
11)	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	16.9%				
12)	TYPE OF REPORTING PERSON				
	IN				
1	Chief Executive Offic	er of Oleoy	s exercised by Mr. Pons in his capacity as l-Estrone Developments SL ("OED"). Mr. Pons f the shares owned by OED.		
		Sch	edule 13G		

Item 1(a). Name of Issuer:

Manhattan Pharmaceuticals, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

787 Seventh Avenue, 48th Floor New York, New York 10019

Item 2(a). Name of Persons Filing:

Oleoyl-Estrone Developments SL

Joan Pons Gimbert

Item 2(b). Address of Principal Business Office or, if None, Residence:

The business address of Oleoyl-Estrone Developments SL is:

Josep Samitier 1-5 Barcelona Science Park 08028 Barcelona, Spain

The business address of Joan Pons Gimbert is:

c/o Oleoyl-Estrone Developments
Josep Samitier 1-5
Barcelona Science Park
08028 Barcelona, Spain

Item 2(c). Citizenship or Place of Organization:

Oleoyl-Estrone Developments  $\operatorname{SL}$  is a company of unlimited duration registered in the Registro Mercantil of Barcelona.

Joan Pons Gimbert is a citizen of Spain.

Item 2(d). Title of Class of Securities:

Common Stock, \$0.001 par value per share

Item 2(e). CUSIP Number:

563118207

- Item 3. If this statement is filed pursuant to ss.ss. 240.13d-1 (b), or 240.13d-2 (b) or (c), check whether the person filing is a:
  - (a) |\_| Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 780)
  - (b)  $|\_|$  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
  - (c) |\_| Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
  - (d) |\_| Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
  - (e) |\_| Investment Adviser in accordance with ss. 240.13d-1 (b) (1) (ii) (E)
  - (f) |\_| Employee benefit plan or endowment fund in accordance with ss. 240.13d-1 (b) (1) (ii) (F)
  - (g) |\_| Parent Holding Company or control person in accordance with ss.240.13d-1(b)(ii)(G)

- (h) |\_| Savings Association as defined in ss.3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
- (i) |\_| Church plan that is excluded from the definition of an investment company under ss.3(c)(15) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
- (j)  $| \_ |$  Group, in accordance with ss.240.13d-1(b)(ii)(J)

#### Item 4. Ownership.

- (a) Amount beneficially owned: 3,957,037
- (b) Percent of class: 16.9%
- (c) Number of shares as to which such person has:
  - (i) Sole power to vote or to direct the vote: 3,957,037
  - (ii) Shared power to vote or to direct the vote: 0
  - (iii) Sole power to dispose or to direct the disposition of: 3,957,037
  - (iv) Shared power to dispose or to direct the disposition of:  $\ensuremath{\text{0}}$
- Item 5. Ownership of Five Percent or Less of a Class.

Not applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable

Item 8. Identification and Classification of Members of the Group.

Not applicable

Item 9. Notice of Dissolution of Group.

Not applicable

Item 10. Certification.

By signing below, each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and to the best knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this Statement is true, complete and correct.

Oleoyl-Estrone Developments SL

By:/s/ Joan Pons Gimbert

\_\_\_\_\_

Joan Pons Gimbert Chief Executive Officer

Joan Pons Gimbert /s/ Joan Pons Gimbert

\_\_\_\_

Joan Pons Gimbert

Dated as of May 24, 2004